1Triumvira Immunologics, Inc., headquartered in Austin, Texas, with research facilities in Hamilton, Canada.

Screening for the study suggests that around 38% of patients with gastric or GEJ adenocarcinomas have tumours that express the claudin 18.2 biomarker in more than 75% of their cells, the threshold ...

The findings could guide future efforts to stimulate the regeneration of sensory hearing cells ... The Maternal Microbiome During Pregnancy Impacts Offspring's Stem Cells in Mice Dec. 11 ...

The findings could guide future efforts to ... Dec. 12, 2024 — Scientists have discovered that our specialized immune cells, called T cells, are what they eat -- their switch from functional to ...

It feels like the Splinter Cell remake has been on its way for a while now, which isn't helped by the fact it's been over two years since we heard anything official about the game. From what we've ...

Claudin 18.2 is a biomarker positively expressed ... the molecule is usually located within tight junctions that connect cells and isn't typically found in other tissues. After cancer develops ...

The disease gets its name because when you have SCD, your red blood cells look like a sickle, which is a C-shaped farm tool. Normal red blood cells are round and pliable. With sickle cell ...

The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Established in 2016, the Human Cell Atlas (HCA) consortium set out to create a comprehensive biological map of cells within the human body. Now progressing into a data integration phase ...

Cell biology is the discipline of biological sciences that studies the structure, physiology, growth, reproduction and death of cells. Research in cell biology uses microscopic and molecular tools ...

ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia).

The FDA granted fast track designation to ALE.P02, an antibody-drug conjugate targeting Claudin-1 (CLDN1), for use in patients with advanced/metastatic CLDN1-positive squamous solid tumors. ALE.P02, ...